Literature DB >> 19074151

Human prion protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in variant Creutzfeldt-Jakob disease infection.

Masaki Hizume1, Atsushi Kobayashi, Kenta Teruya, Hiroaki Ohashi, James W Ironside, Shirou Mohri, Tetsuyuki Kitamoto.   

Abstract

Prion protein gene (PRNP) E219K is a human polymorphism commonly occurring in Asian populations but is rarely found in patients with sporadic Creutzfeldt-Jakob disease (CJD). Thus the polymorphism E219K has been considered protective against sporadic CJD. The corresponding mouse prion protein (PrP) polymorphism variant (mouse PrP 218K) is not converted to the abnormal isoform (PrP(Sc)) and shows a dominant negative effect on wild-type PrP conversion. To define the conversion activity of this human molecule, we herein established knock-in mice with human PrP 219K and performed a series of transmission experiments with human prions. Surprisingly, the human PrP 219K molecule was converted to PrP(Sc) in variant CJD infection, and the conversion occurred more efficiently than PrP 219E molecule. Notably the knock-in mice with PRNP codon 219E/K showed the least efficient conversion compared with their hemizygotes with PRNP codon 219E/0 or codon 219K/0, or homozygotes with PRNP codon 219E/E or codon 219K/K. This phenomenon indicated heterozygous inhibition. This heterozygous inhibition was observed also in knock-in mice with PRNP codon 129M/V genotype. In addition to variant CJD infection, the human PrP 219K molecule is conversion-competent in transmission experiments with sporadic CJD prions. Therefore, the protective effect of PRNP E219K against sporadic CJD might be due to heterozygous inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074151     DOI: 10.1074/jbc.M809254200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Distinctive properties of plaque-type dura mater graft-associated Creutzfeldt-Jakob disease in cell-protein misfolding cyclic amplification.

Authors:  Atsuko Takeuchi; Atsushi Kobayashi; Piero Parchi; Masahito Yamada; Masanori Morita; Shusei Uno; Tetsuyuki Kitamoto
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

2.  Insights into prion biology: integrating a protein misfolding pathway with its cellular environment.

Authors:  Susanne DiSalvo; Tricia R Serio
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

3.  Characterization of variant Creutzfeldt-Jakob disease prions in prion protein-humanized mice carrying distinct codon 129 genotypes.

Authors:  Atsuko Takeuchi; Atsushi Kobayashi; James W Ironside; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

4.  Prion transmission prevented by modifying the β2-α2 loop structure of host PrPC.

Authors:  Timothy D Kurt; Cyrus Bett; Natalia Fernández-Borges; Shivanjali Joshi-Barr; Simone Hornemann; Thomas Rülicke; Joaquín Castilla; Kurt Wüthrich; Adriano Aguzzi; Christina J Sigurdson
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

Review 5.  Heterozygous inhibition in prion infection: the stone fence model.

Authors:  Atsushi Kobayashi; Masaki Hizume; Kenta Teruya; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  Prion       Date:  2009-01-23       Impact factor: 3.931

Review 6.  Molecular pathology of human prion disease.

Authors:  Jonathan D F Wadsworth; John Collinge
Journal:  Acta Neuropathol       Date:  2010-08-08       Impact factor: 17.088

7.  Dominant prion mutants induce curing through pathways that promote chaperone-mediated disaggregation.

Authors:  Susanne DiSalvo; Aaron Derdowski; John A Pezza; Tricia R Serio
Journal:  Nat Struct Mol Biol       Date:  2011-03-20       Impact factor: 15.369

8.  Trans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactor.

Authors:  James C Geoghegan; Michael B Miller; Aimee H Kwak; Brent T Harris; Surachai Supattapone
Journal:  PLoS Pathog       Date:  2009-07-31       Impact factor: 6.823

9.  PRNP variation in UK sporadic and variant Creutzfeldt Jakob disease highlights genetic risk factors and a novel non-synonymous polymorphism.

Authors:  Matthew T Bishop; Catherine Pennington; Craig A Heath; Robert G Will; Richard S G Knight
Journal:  BMC Med Genet       Date:  2009-12-26       Impact factor: 2.103

10.  Glycoform-selective prion formation in sporadic and familial forms of prion disease.

Authors:  Xiangzhu Xiao; Jue Yuan; Stéphane Haïk; Ignazio Cali; Yian Zhan; Mohammed Moudjou; Baiya Li; Jean-Louis Laplanche; Hubert Laude; Jan Langeveld; Pierluigi Gambetti; Tetsuyuki Kitamoto; Qingzhong Kong; Jean-Philippe Brandel; Brian A Cobb; Robert B Petersen; Wen-Quan Zou
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.